PROCEPT BioRobotics Corp. to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference, scheduled for January 10, 2023, at 9:45 a.m. Pacific Time. The event will feature a presentation by the company's management team. Interested parties can access a live webcast and an archived recording through the company’s website.

PROCEPT BioRobotics focuses on innovating surgical robotics for urology, specifically addressing benign prostatic hyperplasia (BPH) through its AquaBeam Robotic System, which is backed by extensive clinical evidence.

REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- PROCEPT^® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 41^st Annual J.P. Morgan Healthcare Conference. Management is scheduled to present on Tuesday, January 10 at 9:45 a.m. Pacific Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:
Matt Bacso, CFA
VP, Investor Relations and Business Operations
m.bacso@PROCEPT-BioRobotics.com

FAQ

When will PROCEPT BioRobotics present at the J.P. Morgan Healthcare Conference?

PROCEPT BioRobotics will present on January 10, 2023, at 9:45 a.m. Pacific Time.

How can I watch the PROCEPT BioRobotics presentation at the conference?

You can watch the live webcast and access the archived recording on the Investors section of PROCEPT BioRobotics' website.

What is the focus of PROCEPT BioRobotics Corporation?

PROCEPT BioRobotics focuses on developing surgical robotics solutions in urology, particularly for treating benign prostatic hyperplasia (BPH).

What is the AquaBeam Robotic System?

The AquaBeam Robotic System is an advanced, image-guided surgical system designed for minimally-invasive urologic surgery, primarily for BPH treatment.

What evidence supports the effectiveness of Aquablation therapy?

Aquablation therapy is supported by nine clinical studies and over 100 peer-reviewed publications demonstrating its benefits.